MediWound (MDWD) said Thursday it will start a phase II clinical study in 2025 evaluating EscharEx versus a collagenase ointment that's marketed as Santyl in the US and Iruxol in Europe to treat venous leg ulcers.
The study will enroll 45 patients in the US and Europe and will run concurrently with the company's phase III trial in venous leg ulcer patients.
MediWound said the study is designed to support the biologics license application for EscharEx.
The company's shares were up nearly 1% in recent trading.
Price: 16.65, Change: +0.15, Percent Change: +0.91
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.